On Monday, it was announced that Arcturus Therapeutics is actively seeking a green light from the FDA to begin Phase 1 trials for self-replicating “vaccines” against bird flu.
Except perhaps for the genetic code contained within them, these are the same injections that were rolled out last month in Japan and which the Japanese have been referring to as the “third atomic bomb” because the effects could be so devastating.
Self-amplifying RNA (“saRNA”), also termed self-replicating RNA (“srRNA”), and self-amplifying mRNA (“sa-mRNA” or “samRNA”) are synonymous terms. Both refer to a synthetic mRNA molecule engineered to replicate itself within host cells. Vaccines using this self-replicating technology are also called “replicon” vaccines.
In November 2023, Japan approved the use of the first saRNA vaccine against covid. The vaccine is called Kostaive and is also known as ARCT-154 or, in Vietnam, VBC-COV19-154. It is a CSL and Arcturus Therapeutics vaccine.
At the time of the approval, researchers were hopeful that this was only the beginning for saRNA treatments for infectious diseases and even cancers. The vaccine, which the Japanese are referring to as the “third atomic bomb,” began to be rolled out in Japan in October 2024 as part of its autumn covid vaccination programme.
There is only explicit mention of Kostaive using STARR mRNA technology. However, it is likely that the Kostaive “vaccine” uses both of Arcturus Therapeutics’ proprietary technologies: STARR (self-transcribing and replicating RNA) mRNA technology and LUNAR (lipid-mediated universal RNA delivery) delivery system.
LUNAR is a nanoparticle delivery system that enables the efficient and targeted delivery of mRNA to cells. STARR is a self-replicating RNA platform that combines with LUNAR to drive “therapeutic” protein expression.
Read more:
- Self-replicating vaccines due to be rolled out next month in Japan could result in a worldwide disaster
- Japan: Replicon “vaccines” could turn people into mobile “vaccine” factories
- The Third Atomic Bomb: Self-replicating RNA vaccines
Yesterday, American attorney Tom Renz tweeted some alarming news; Arcturus is seeking approval from the US Food and Drug Administration (“FDA”) to begin a Phase 1 study for ARCT-2304, a sa-mRNA vaccine against H5N1 influenza (bird flu). Renz was highlighting an announcement on Monday publicised by Business Wire.
The vaccine they are attempting to advance to trials uses Arcturus Therapeutics’ STARR self-amplifying mRNA technology. It is a sa-mRNA vaccine formulated within a lipid nanoparticle (“LNP”). There is no specific mention that the LNP used is Arcturus Therapeutics’ LUNAR delivery system but it’s logical that it would be. In other words, ARCT-2304 is the same as the “third atomic bomb” that was rolled out in Japan beginning in October except perhaps for the genetic code used, RNA or mRNA.
Worse, RNA and RNA-type molecules are known to shed. This can be done through contact, sex, and even through the air. This means there is potential for someone “infected” with such a “vaccine” to spread this poison to others. It is even more possible in light of the fact that the self-amplification keeps the levels of these poisons in the host high even well after getting the shot.
These poisons are the ultimate workaround for any issues of informed consent and MAY be more likely to alter your DNA due to their perpetual presence. Why do we need these for the flu and why not have the full years-long testing to show they are safe and effective if there is no emergency?
No comments:
Post a Comment